학술논문
Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): An open-label, randomised phase 3 trial
Document Type
Article
Author
Source
In: The Lancet Oncology . (The Lancet Oncology, 1 October 2014, 15(11):1269-1278)
Subject
Language
English
ISSN
14745488
14702045
14702045